• Home
  • Ivosidenib 250mg
  • Ivosidenib 250mg

Ivosidenib 250mg

52111

Ivosidenib is used for acute myeloid leukaemia with an IDH1 mutation, including newly diagnosed disease in people who cannot have intensive chemotherapy and disease that has come back or not responded.

It is also used for previously treated cholangiocarcinoma that has spread or cannot be removed by surgery and has an IDH1 mutation.

In some countries, it is used for relapsed or refractory myelodysplastic syndromes with an IDH1 mutation.

Usual adult dose: 500mg once daily, with adjustments if side effects or interacting medicines require a change.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.